JPMorgan chimes in on Edward Lifesciences (EW -0.9%), noting that a FDA panel delay on Sapein...


JPMorgan chimes in on Edward Lifesciences (EW -0.9%), noting that a FDA panel delay on Sapein until June will keep the suspense in place for an extra month on the outcome for broader use of the heart valve. Analysts with JP have a Neutral rating on the company.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs